van der Feltz-Cornelis CM, Nuyen J, Stoop C et al (2010) Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis
Robert Kushner: That article has been a paradigm shift and there's been so many follow-up articles in response to it with other types of studies that are addressing it
But I think theres also probably going to be 5 or 10 new medications that come to market in the next few years, just given if you look at the clinical studies and the FDA pipeline
This can help restart the weight loss process
Lydia Alexander, past president of the Obesity Medicine Association
NEWS AND VIEWS Genetic variants in GLP1R and GIPR , which encode targets of GLP-1-based medications, offer insights into why responses to these drugs vary and who might face adverse effects